Viewing data from:

CEFIXIME

ANDA

CEFIXIME | A210574 | ALKEM LABORATORIES LTD

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: SUPRAX(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 2 NDCs

Highest NADAC/Unit

$10.09

per ea

Lowest NADAC/Unit

$10.09

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
67877058433CEFIXIME 400 MG CAPSULE	$10.09	EA	Generic	—	2026-06-17
67877058450CEFIXIME 400 MG CAPSULE	$10.09	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain10 active DMFs6 inactive

10 active API suppliers hold Drug Master Files for this ingredient.

LUPIN LTDCEFIXIME USP

DMF 159962002

NECTAR LIFESCIENCES LTDCEFIXIME USP

DMF 193072006

ORCHID PHARMA LTDCEFIXIME (PROCESS 2)

DMF 199602006

PURE AND CURE HEALTHCARE PRIVATE LTDCEFIXIME

DMF 234742010

UNIMARK REMEDIES LTDCEFIXIME USP

DMF 260472012

APITORIA PHARMA PRIVATE LTDCEFIXIME USP (NON-STERILE DRUG SUBSTANCE)

DMF 263692012

COVALENT LABORATORIES PRIVATE LTDCEFIXIME USP

DMF 271212013

SANDOZ GMBHCEFIXIME

DMF 275272013

QILU ANTIBIOTICS PHARMACEUTICAL CO LTDCEFIXIME

DMF 366942022

ZHEJIANG APELOA TOSPO PHARMACEUTICAL CO LTDCEFIXIME

DMF 416512025

ASTELLAS PHARMA INCInactiveCEFIXIME

DMF 94781991

LEDERLE LABORATORIESInactiveCEFIXIME

DMF 136871998

SANDOZ PRIVATE LTDInactiveCEFIXIME

DMF 163132002

ORCHID CHEMICALS AND PHARMACEUTICALS LTDInactiveCEFIXIME, USP

DMF 176552004

CSPC ZHONGNUO PHARMACEUTICAL SHIJIAZHUANG CO LTDInactiveCEFIXIME NON-STERILE

DMF 253902011

KYONGBO PHARMACEUTICAL CO LTDInactiveCEFIXIME BULK

DMF 270332013

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Nov 15, 2018	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 400MG

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Oct 9, 2018

No patent or exclusivity listings for this strength.